Comparison of an antimetabolic assay and an antiproliferative assay, both using 3 h‐thymidine incorporation, to test drug sensitivity of human tumors
| Autor: | Nadia Zaffaroni, Cinzia Demarco, Raffaella Villa, Rosella Silvestrini, Egle Grignolio |
|---|---|
| Rok vydání: | 1988 |
| Předmět: |
Drug
Antimetabolites Antineoplastic medicine.drug_class media_common.quotation_subject Antineoplastic Agents Biology Antimetabolite Colony-Forming Units Assay Bleomycin chemistry.chemical_compound Neoplasms medicine Humans Tumor Stem Cell Assay media_common Dose-Response Relationship Drug Melanoma In vitro toxicology Cell Biology Cell cycle medicine.disease Molecular biology In vitro Mechanism of action chemistry Doxorubicin Vincristine Immunology Cisplatin Drug Screening Assays Antitumor medicine.symptom Thymidine |
| Zdroj: | The International Journal of Cell Cloning. 6:392-403 |
| ISSN: | 0737-1454 |
| DOI: | 10.1002/stem.5530060604 |
| Popis: | Two assays based on the inhibition of 3H-thymidine incorporation into DNA were used to measure either the antimetabolic or the antiproliferative effects of anticancer drugs. A direct comparison of the two assays was made with cell suspensions obtained from 11 ovarian cancers and 22 malignant melanomas. Drugs with different effects on cell cycle phases were tested by both assays, for a total of 53 drug comparisons. When the sensitivity indices specific for each system was used, a significant association (p less than 0.01) was noted between the two assays. The agreement of both assays in defining in vitro sensitivity or resistance was 100% for ovarian cancer. For melanoma, 97% of samples resistant to the antimetabolic assay were also resistant to the antiproliferative assay; whereas, only 45% of samples sensitive to the antimetabolic assay were sensitive to the antiproliferative assay. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text